Compras y ventas de directivos de Thermo Fisher Scientific (TMO)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de Thermo Fisher Scientific Inc. (TMO): ninguna compra y 34 ventas
109 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de Thermo Fisher Scientific Inc. entre el 2025-08-26 y el 2026-09-01 (histórico de 15 meses): 0 compras y 34 ventas en mercado abierto, y 75 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $18,7M de Lagarde Michel el 2025-12-03.
Compras y ventas de directivos de Thermo Fisher Scientific en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de Thermo Fisher Scientific declararon 31 ventas por $158,1M en mercado abierto, y ninguna compra.
Quien más vendió fue Casper Marc N (Chairman & CEO): $53,9M en 11 ventas, de 7 vendedores distintos.
La mayor operación del período fue una venta de $18,7M el 3 dic 2025, de Lagarde Michel (Executive Vice President & COO). Formulario 4 en sec.gov (0000097745-25-000178).
De las 31 ventas, 22 (el 71%, $89,7M) llevan en el Formulario 4 la marca de plan 10b5-1, es decir, se programaron con meses de antelación; las otras 9 no la llevan.
En los tres últimos meses hay 12 ventas, frente a 1 en los tres anteriores. La última venta es del 31 ago 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. Thermo Fisher Scientific tiene más ventas que 52 de las otras 58, es la 6.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra.
Las 20 operaciones más importantes
Como TMO no tiene compras en mercado abierto, la tabla empieza por sus ventas, de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 109 operaciones de TMO en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2025-12-03 | 2025-12-04 | Lagarde Michel | Executive Vice President & COO | $18,7M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.03 to $583.96, inclusive. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.00 to $584.533, inclusive. | SEC |
| 2025-12-02 | 2025-12-04 | Lagarde Michel | Executive Vice President & COO | $17,5M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.90 to $582.33, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. | SEC |
| 2026-08-11 | 2026-08-13 | Shafer Michael D | Executive Vice President | $15,3M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. | SEC |
| 2025-12-04 | 2025-12-05 | Lagarde Michel | Executive Vice President & COO | $12,4M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.38 to $564.20, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2025-10-24 | 2025-10-28 | Casper Marc N | Chairman & CEO | $9,8M | S — Venta en mercado abierto (programada 10b5-1)6 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.73 to $571.72, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16) and (17) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.75 to $572.74, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.75 to $573.74, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.76 to $574.75, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.76 to $575.67, inclusive. | SEC |
| 2026-08-05 | 2026-08-07 | Casper Marc N | Chairman & CEO | $8,6M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: By Floral Park Associates, Inc. 14 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.42 to $568.36, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.56 to $569.55, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.18 to $572.03, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.36 to $573.34, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.45 to $574.42, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.48 to $575.47, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.48 to $576.47, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.48 to $577.42, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.49 to $577.63, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.86 to $566.63, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.55 to $569.50, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.55 to $569.76, inclusive. | SEC |
| 2026-08-06 | 2026-08-07 | Casper Marc N | Chairman & CEO | $8,6M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: By Floral Park Associates, Inc. 19 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.56 to $571.53, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18) and (19) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.83 to $572.78, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.94 to $573.93, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.94 to $574.92, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.00 to $575.95, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.10 to $577.03, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.14 to $578.13, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.14 to $579.13, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.28 to $580.07, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.56 to $571.45, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.70 to $572.67, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.90 to $573.87, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.91 to $574.70, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.02 to $576.01, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $576.08 to $576.11, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.18 to $578.06, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.54 to $579.11, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.97 to $580.06, inclusive. | SEC |
| 2026-08-19 | 2026-08-20 | Britt Lisa P. | Sr. VP and Chief HR Officer | $7,0M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $613.09 to $613.49, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2025-11-25 | 2025-11-26 | Shafer Michael D | Executive Vice President | $6,4M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2024. | SEC |
| 2026-08-20 | 2026-08-24 | Casper Marc N | Chairman & CEO | $6,3M | S — Venta en mercado abierto (programada 10b5-1)9 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. | SEC |
| 2026-08-21 | 2026-08-24 | Casper Marc N | Chairman & CEO | $6,3M | S — Venta en mercado abierto (programada 10b5-1)6 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. | SEC |
| 2025-11-07 | 2025-11-10 | Britt Lisa P. | Sr. VP and Chief HR Officer | $5,8M | S — Venta en mercado abierto | SEC |
| 2025-08-22 | 2025-08-26 | Casper Marc N | Chairman & CEO | $5,0M | S — Venta en mercado abierto (programada 10b5-1)4 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.001 to $500.98, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.05 to $501.99, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.02 to $502.37, inclusive. | SEC |
| 2025-12-01 | 2025-12-03 | Lowery Frederick M. | Executive Vice President | $4,1M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. | SEC |
| 2025-10-27 | 2025-10-28 | Casper Marc N | Chairman & CEO | $4,1M | S — Venta en mercado abierto (programada 10b5-1)12 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2025. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $561.04 to $561.97, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $562.07 to $563.02, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.08 to $564.07, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $564.08 to $565.07, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $565.08 to $565.97, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $566.14 to $566.68, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $567.14 to $568.13, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $568.32 to $569.27, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $569.42 to $570.41, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.43 to $571.39, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.48 to $572.27, inclusive. | SEC |
| 2025-12-02 | 2025-12-03 | Lowery Frederick M. | Executive Vice President | $4,0M | S — Venta en mercado abierto (programada 10b5-1)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. | SEC |
| 2026-08-06 | 2026-08-07 | Britt Lisa P. | Sr. VP and Chief HR Officer | $3,4M | S — Venta en mercado abierto | SEC |
| 2026-08-07 | 2026-08-10 | Casper Marc N | Chairman & CEO | $2,9M | S — Venta en mercado abierto (programada 10b5-1) Tenencia indirecta, a través de: By Floral Park Associates, Inc. 13 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. | SEC |
| 2025-11-13 | 2025-11-14 | Lagarde Michel | Executive Vice President & COO | $2,8M | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $594.36 to $594.88, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-03-04 | 2026-03-05 | Casper Marc N | Chairman & CEO | $2,6M | S — Venta en mercado abierto (programada 10b5-1)9 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.283 to $510.22, inclusive. F15 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $510.32 to $511.277, inclusive. F16 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.323 to $512.303, inclusive. F17 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.34 to $513.33, inclusive. F18 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.341 to $514.328, inclusive. F19 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.383 to $515.373, inclusive. F20 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.378 to $516.065, inclusive. F21 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.57 to $517.046, inclusive. | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 26 ago 2025 y el 1 sept 2026 no consta ni una compra en mercado abierto de Thermo Fisher Scientific Inc.: 34 ventas por $163,5M y cero dólares comprados.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de Thermo Fisher Scientific Inc. salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| S | Venta en mercado abierto | 34 | $163,5M |
| M | Ejercicio de opciones | 28 | $69,5M |
| F | Retención fiscal (acciones entregadas por impuestos) | 26 | $10,6M |
| A | Adjudicación o premio de acciones | 19 | $0 |
| G | Regalo o donación | 2 | $0 |
| Total | Todo lo declarado en el período | 109 | $243,6M |
21 de las 109 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de Thermo Fisher Scientific Inc. 20 personas o entidades distintas. De ellas, ninguna compró en mercado abierto y 7 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
De los 7 que vendieron en mercado abierto (34 ventas en total), los tres que más vendieron suman $132,9M de los $163,5M: el 81% del dinero en tres personas.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| Casper Marc N | Chairman & CEO | 30 | — | $59,1M (13) | 2026-09-01 |
| Lagarde Michel | Executive Vice President | 11 | — | $51,3M (4) | 2026-03-02 |
| Shafer Michael D | Executive Vice President | 9 | — | $22,5M (3) | 2026-09-01 |
| Britt Lisa P. | Sr. VP and Chief HR Officer | 11 | — | $16,9M (4) | 2026-09-01 |
| Lowery Frederick M. | Executive Vice President | 7 | — | $8,2M (2) | 2026-03-02 |
| Pettiti Gianluca | President & COO | 12 | — | $5,1M (6) | 2026-09-01 |
| Holmes Joseph R. | VP & Chief Accounting Officer | 8 | — | $435k (2) | 2026-09-01 |
| Williamson Stephen | Retiring Sr. VP and CFO | 4 | — | — | 2026-03-02 |
Se enseñan los 8 que más dinero movieron, de 20. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue ago 2026: 0 compras y 11 ventas, por $61,3M. 5 de los 15 meses no tienen ninguna.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 2 | $5,2M |
| sept 2025 | 0 | $0 | 1 | $200k |
| oct 2025 | 0 | $0 | 3 | $14,1M |
| nov 2025 | 0 | $0 | 5 | $17,4M |
| dic 2025 | 0 | $0 | 5 | $56,7M |
| ene 2026 | 0 | $0 | 0 | $0 |
| feb 2026 | 0 | $0 | 1 | $216k |
| mar 2026 | 0 | $0 | 4 | $7,9M |
| abr 2026 | 0 | $0 | 1 | $185k |
| may 2026 | 0 | $0 | 0 | $0 |
| jun 2026 | 0 | $0 | 0 | $0 |
| jul 2026 | 0 | $0 | 1 | $226k |
| ago 2026 | 0 | $0 | 11 | $61,3M |
| sept 2026 | 0 | $0 | 0 | $0 |
| oct 2026 | 0 | $0 | 0 | $0 |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de Thermo Fisher Scientific Inc. (TMO) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
13 de las 20 ventas de la tabla van marcadas como programadas (plan 10b5-1): se firman con meses de antelación y se ejecutan solas, así que no dicen lo que el directivo piensa hoy. Thermo Fisher Scientific no tiene ninguna compra en mercado abierto (código P) en el histórico, que es lo más común en el S&P 500: los directivos ya cobran en acciones. La última presentación es del 1 sept 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
18 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.